Abstract
We studied the association between clinical outcome in MS and allelic variants single nucleotide polymorphisms (SNPs) of interleukin-1alpha (IL-1alpha), IL-1beta and a variable number tandem repeat (VNTR) in IL-1 receptor antagonist (IL-1RN). A total of 377 patients with MS were studied. Significant associations between IL-1 genotypes and clinical outcome were found using logistic regression after correction for gender, onset age and disease duration. The same trends were subsequently demonstrated in a second independent group of 67 primary progressive patients. Our results suggest that genetically determined immunomodulation mediated by IL-1 influences long-term prognosis in multiple sclerosis (MS).
MeSH terms
-
Adjuvants, Immunologic / genetics*
-
Adult
-
Age of Onset
-
Case-Control Studies
-
Disease Progression
-
Female
-
Gene Frequency / genetics
-
Genetic Predisposition to Disease / genetics*
-
Genotype
-
Homozygote
-
Humans
-
Interleukin 1 Receptor Antagonist Protein
-
Interleukin-1 / genetics*
-
Interleukin-1 / immunology
-
Linkage Disequilibrium / genetics
-
Male
-
Middle Aged
-
Multiple Sclerosis / genetics*
-
Multiple Sclerosis / immunology*
-
Multiple Sclerosis / physiopathology
-
Polymorphism, Genetic / genetics*
-
Polymorphism, Genetic / immunology
-
Sex Factors
-
Sialoglycoproteins / genetics*
-
Sialoglycoproteins / immunology
Substances
-
Adjuvants, Immunologic
-
IL1RN protein, human
-
Interleukin 1 Receptor Antagonist Protein
-
Interleukin-1
-
Sialoglycoproteins